|
KMID : 1100820160060040193
|
|
Laboratory Medicine Online
2016 Volume.6 No. 4 p.193 ~ p.213
|
|
|
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 2
|
|
Kim Sol-Iip
Yun Yeo-Min
Kim In-Suk
Song Sang-Hoon
Woo Hye-In
Lee Kyung-A
Lee Woo-Chang
Cho Hyun-Jung
Ji Mi-Suk
Chae Hyo-Jin
Lee Soo-Youn
Chun Sa-Il
|
|
|
Abstract
|
|
|
|
Pharmacogenetics is a rapidly evolving field and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation of pharmacogenetic tests in clinical practice may result in a rise in medical costs and adverse outcomes in patients. This document suggests guidelines for the clinical application, interpretation, and reporting of pharmacogenetic test results based on a literature review and the collection of evidence-based expert opinions. The clinical laboratory practice guidelines encompass the clinical pharmacogenetic tests covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic tests have also been addressed. In particular, this document comprises the following pharmacogenetic tests: CYP2C9 and VKORC1 for warfarin, CYP2C19 for clopidogrel, CYP2D6 for tricyclic antidepressants, codeine, tamoxifen, and atomoxetine, NAT2 for isoniazid, UGT1A1 for irinotecan, TPMT for thiopurines, EGFR for tyrosine kinase inhibitors, ERBB2 (HER2) for erb-b2 receptor tyrosine kinase 2-targeted therapy, and KRAS for anti-epidermal growth factor receptor drugs. These guidelines would help improve the usefulness of pharmacogenetic tests in routine clinical settings.
|
|
|
KEYWORD
|
|
|
Pharmacogenetics, Genetic testing, Practice guidelines, Clinical laboratory services
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|